First-Line Options and PAPILLON Survival Data in EGFR Exon 20 NSCLC

"First-Line Options and PAPILLON Survival Data in EGFR Exon 20 NSCLC" brings together Dr. Yu's impressions of the evolving evidence and the latest overall survival findings.

Dr. Yu begins by cautioning that cross-trial comparisons cannot settle which agent is best. Three first-line approaches are now in view: chemotherapy with amivantamab, chemotherapy with zipalertinib, and sunvozertinib monotherapy. Numerically, progression-free survival was highest with chemotherapy plus zipalertinib, followed by chemotherapy plus amivantamab, then sunvozertinib alone. She repeats that these figures come from separate trials.

Side effect profiles also distinguish the regimens. Chemotherapy with amivantamab produces more EGFR- and MET-directed toxicities. Chemotherapy with zipalertinib showed additive cytopenias, which she flags as a potential issue to watch. Sunvozertinib offers the convenience of oral dosing but causes diarrhea more often than the other two options. Dr. Yu suggests that CNS efficacy may ultimately separate these agents. CNS data exist for amivantamab and zipalertinib, while sunvozertinib has been studied less in this respect. She believes deeper analysis of that evidence could clarify which agent is most efficacious and should be used first.

Dr. Yu then reviews final overall survival results from PAPILLON, presented at the World Conference on Lung Cancer 2026. The amivantamab and chemotherapy regimen has been FDA approved in the US since the study's initial results were reported several years ago. PAPILLON allowed patients on the chemotherapy arm to receive amivantamab in the second-line setting. She explains that crossover inevitably narrows the observed survival difference between arms. Even so, median overall survival reached 34.3 months with amivantamab plus chemotherapy versus 27.9 months with chemotherapy alone. She considers that difference clinically meaningful for patients. A statistical analysis adjusting for crossover showed an even larger survival benefit for the combination arm. Taken together, the data confirm durable benefit for the current standard while new options compete for a place alongside it.

Our next episode, "Oral TKIs, CNS Activity, and Pipeline Data in EGFR Exon 20 NSCLC," turns to first-line oral monotherapy, the growing importance of brain penetration, and results from across the development pipeline.